SCHEMBL9528515

SCHEMBL9528515

NCCNc1nc(N)nc(N)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 3/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CXCR4 P61073 1/20 0.40
HTR7 P34969 11/20 0.38
HTR6 P50406 8/20 0.38
HTR1A P08908 7/20 0.38
DRD2 P14416 7/20 0.38
HTR2A P28223 7/20 0.38
NPSR1 Q6W5P4 1/20 0.35
ADRA1D P25100 2/20 0.33
ADRA1A P35348 2/20 0.33
ADRA1B P35368 2/20 0.33
HRH3 Q9Y5N1 1/20 0.33
HTR2C P28335 1/20 0.33
CASP1 P29466 1/20 0.33
GPR68 Q15743 1/20 0.33
CA12 O43570 1/20 0.32
CA3 P07451 1/20 0.32
CA4 P22748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18062209 0.95 CA1 (0.41) CA9CA1CA2CXCR4HTR7
SCHEMBL9528787 0.95 CA1 (0.40) CA9CA1CA2CXCR4HTR7
SCHEMBL17577086 0.93 CA1 (0.39) CA9CA1CA2CXCR4HTR7
SCHEMBL380440 0.87 CA1 (0.47) CA9CA1CA2HTR7HTR6
SCHEMBL22931512 0.87 HRH3 (0.44) CA9CA1CA2CXCR4HTR7
SCHEMBL14128217 0.86 HRH3 (0.47) CA9CA1CA2HTR7HTR6
SCHEMBL18466743 0.85 HSP90AA1 (0.37) CA9CA1CA2CXCR4HTR7
SCHEMBL15294299 0.84 HTR7 (0.45) CA9CA1CA2HTR7HTR6
SCHEMBL430482 0.84 CXCR4 (0.40) CA9CA1CA2CXCR4CA12
SCHEMBL17826472 0.83 LMNA (0.45) CA9CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110885394-A Triazine group modified macroporous resin and preparation method thereof 万华化学集团股份有限公司 2020-03-17 CN claimed
US-12404287-B2 Chemical compound, surface treating agent, surface treating method, and production method for metal-resin composite MEC COMPANY LTD. (JP) 2025-09-02 US disclosed
CN-118420553-B Compound, surface treatment agent, surface treatment method, and method for producing metal-resin composite MEC股份有限公司 2025-04-08 CN disclosed
US-20240270763-A1 CHEMICAL COMPOUND, SURFACE TREATING AGENT, SURFACE TREATING METHOD, AND PRODUCTION METHOD FOR METAL-RESIN COMPOSITE MEC COMPANY LTD. (JP) 2024-08-15 US disclosed
EP-4410798-A1 CHEMICAL COMPOUND, SURFACE TREATING AGENT, SURFACE TREATING METHOD, AND PRODUCTION METHOD FOR METAL-RESIN COMPOSITE MEC COMPANY., LTD. (JP) 2024-08-07 EP disclosed
CN-118420553-A Compound, surface treatment agent, surface treatment method, and method for producing metal-resin composite MEC股份有限公司 2024-08-02 CN disclosed
WO-2023067121-A1 OLIGOSACCHARIDE COMPOUNDS AND COMPLEXES BioNTech SE (DE) 2023-04-27 WO disclosed
WO-2023067125-A1 OLIGOSACCHARIDE COMPLEXES AND USES BioNTech SE (DE) 2023-04-27 WO disclosed
WO-2023067123-A1 OLIGOSACCHARIDE COMPLEXES AND USES BioNTech SE (DE) 2023-04-27 WO disclosed
CN-110885394-B Triazine group modified macroporous resin and preparation method thereof 万华化学集团股份有限公司 2022-03-11 CN disclosed
CN-110885394-A Triazine group modified macroporous resin and preparation method thereof 万华化学集团股份有限公司 2020-03-17 CN disclosed
EP-2298839-B1 WEATHER-RESISTANT DYE AND THE USE THEREOF ZHUHAI NINESTAR MAN CO LTD (CN) 2017-05-31 EP disclosed
US-9382215-B2 Therapeutic methods and agents for treating myotonic dystrophy THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2016-07-05 US disclosed
US-20140288080-A1 THERAPEUTIC METHODS AND AGENTS FOR TREATING MYOTONIC DYSTROPHY THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-09-25 US disclosed
US-8754084-B2 Therapeutic methods and agents for treating myotonic dystrophy THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-06-17 US disclosed
US-20130261124-A1 THERAPEUTIC METHODS AND AGENTS FOR TREATING MYOTONIC DYSTROPHY THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2013-10-03 US disclosed
CN-102066451-A Hyperbranched polymers and oligomers containing terminal amino groups as curing agents for epoxy resins BASF SE 2011-05-18 CN disclosed
EP-0179408-B1 AMIDOALKYL MELAMINES AND AMINOALKYL MELAMINES, AND PROCESS FOR THEIR PREPARATION BASF Aktiengesellschaft (DE) 1993-09-08 EP disclosed
US-4670558-A POLYURETHANE INTERMEDIATES BASF AKTIENGESELLSCHAFT (DE) 1987-06-02 US disclosed
EP-0179408-A2 Amidoalkyl melamines and aminoalkyl melamines, and process for their preparation BASF Aktiengesellschaft (DE) 1986-04-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288080-A1 THERAPEUTIC METHODS AND AGENTS FOR TREATING MYOTONIC DYSTROPHY POLRMT, SMN1; SMN2, MTPN CA9 4662/4885CA1 4676/4885CA2 3528/4885
US-12404287-B2 Chemical compound, surface treating agent, surface treating method, and production method for metal-resin composite ASH2L, H1-0, MARS1 CA9 1540/4885CA1 537/4885CA2 957/4885
US-20130261124-A1 THERAPEUTIC METHODS AND AGENTS FOR TREATING MYOTONIC DYSTROPHY POLRMT, SMN1; SMN2, MTPN CA9 4662/4885CA1 4676/4885CA2 3528/4885
US-20240270763-A1 CHEMICAL COMPOUND, SURFACE TREATING AGENT, SURFACE TREATING METHOD, AND PRODUCTION METHOD FOR METAL-RESIN COMPOSITE ASH2L, H1-0, MARS1 CA9 1540/4885CA1 537/4885CA2 957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.